The association between oral contraceptives, depot-medroxyprogesterone acetate, and trichomoniasis

Sexually Transmitted Diseases

Volumn 36, Issue 6, 2009, Pages 336-340

  Torok, Michelle R ^a,e   Miller, William C ^a   Hobbs, Marcia M ^b   MacDonald, Pia D M ^a   Leone, Peter A ^a,c   Schwebke, Jane R ^d   Seña, Arlene C ^a,c  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d University of Alabama at Birmingham   (United States)

^e NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; INFECTION RISK; MULTIVARIATE ANALYSIS; ORAL CONTRACEPTION; PROSPECTIVE STUDY; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TRICHOMONAS VAGINALIS; TRICHOMONIASIS;

EID: 67049100337     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318199723f     Document Type: Article

References (49)

1. WHO. Global prevalence and incidence of selected curable sexually transmitted infections. Geneva, Switzerland: WHO, 2001.
2. Cotch M, Pastorek J, Nugent R, et al. Demographic and behavioral predictors of Trichomonas vaginalis infection among pregnant women. Obstet Gynecol 1991; 78:1087-1092.
3. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS 1993; 7:95-102.
4. Soper D. Trichomoniasis: Under control or undercontrolled? Am J Obstet Gynecol 2004; 190:281-290.
5. Sorvillo F, Smith L, Kerndt P, et al. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 2001; 7:927-932.
6. Brabin L. Hormonal markers of susceptibility to sexually transmitted infections: Are we taking them seriously? BMJ 2001; 323:394-395.
7. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. Am J Obstet Gynecol 2001; 185:380-385.
8. Jacobson DL, Peralta L, Farmer M, et al. Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents. Sex Transm Dis 2000; 27:313-319.
9. Ceruti M, Canestrelli M, Condemi V, et al. Methods of contraception and rates of genital infections. Clin Exp Obstet Gynecol 1994; 21:119-123.
10. United Nations. World Contraceptive Use 2005, Vol. 2006; 2005.
11. Avonts D, Sercu M, Heyerick P, et al. Incidence of uncomplicated genital infections in women using oral contraception or an intra-uterine device: A prospective study. Sex Transm Dis 1990; 17: 23-29.
12. Moi H. Prevalence of bacterial vaginosis and its association with genital infections, inflammation, and contraceptive methods in women attending sexually transmitted disease and primary health clinics. Int J STD AIDS 1990; 1:86-94.
13. McGregor J, Hammill H. Contraception and sexually transmitted diseases: Interactions and opportunities. Am J Obstet Gynecol 1993;168:2033-2041.
14. Oh MK, Feinstein RA, Soileau EJ, et al. Chlamydia trachomatis cervical infection and oral contraceptive use among adolescent girls. J Adolesc Health Care 1989; 10:376-381.
15. Gertig DM, Kapiga SH, Shao JF, et al. Risk factors for sexually transmitted diseases among women attending family planning clinics in Dar-es-Salaam, Tanzania. Genitourin Med 1997; 73: 39-43.
16. Sonnex C. Influence of ovarian hormones on urogenital infection. Sex Transm Inf 1998; 74:11-19.
17. Morrison CS, Bright P, Wong EL, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis 2004; 31:561-567.
18. Mohllajee AP, Curtis KM, Martins SL, et al. Hormonal contraceptive use and risk of sexually transmitted infections: A systematic review. Contraception 2006; 73:154-165.
19. Lefevre JC, Averous S, Bauriaud R, et al. Lower genital tract infections in women: Comparison of clinical and epidemiologic findings with microbiology. Sex Transm Dis 1988; 15:110-113.
20. Bramley M, Kinghorn G. Do oral contraceptives inhibit Trichomonas vaginalis? Sex Transm Dis 1979; 6:261-263.
21. Fouts AC, Kraus SJ. Trichomonas vaginalis: Reevaluation of its clinical presentation and laboratory diagnosis. J Infect Dis 1980; 141:137-143.
22. Barbone F, Austin H, Louv WC, et al. A follow-up study of methods of contraception, sexual activity, and rates of trichomo-niasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990; 163:510-514.
23. Pereira LH, Embil JA, Haase DA, et al. Cytomegalovirus infection among women attending a sexually transmitted disease clinic: Association with clinical symptoms and other sexually transmitted diseases. Am J Epidemiol 1990; 131:683-692.
24. Staerfelt F, Gundersen TJ, Halsos AM, et al. A survey of genital infections in patients attending a clinic for sexually transmitted diseases. Scand J Infect Dis Suppl 1983; 40:53-57.
25. Kinghorn GR, Waugh MA. Oral contraceptive use and prevalence of infection with Chlamydia trachomatis in women. Br J Vener Dis 1981; 57:187-190.
26. Nsofor BI, Bello CS, Ekwempu CC. Sexually transmitted disease among women attending a family planning clinic in Zaria, Nigeria. Int J Gynaecol Obstet 1989; 28:365-367.
27. Lavreys L, Chohan V, Overbaugh J, et al. Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS 2004; 18:2179-2184.
28. Kazerooni T, Mosalaee A. Does contraceptive method change the Pap smear finding? Contraception 2002; 66:243-246.
29. Sena AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007; 44:13-22.
30. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
31. Reed BD, Huck W, Zazove P. Differentiation of Gardnerella vaginalis, Candida albicans, and Trichomonas vaginalis infections of the vagina. J Fam Pract 1989; 28:673-680.
32. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698-702.
33. Cottingham J, Hunter D. Chlamydia trachomatis and oral contraceptive use: A quantitative review. Genitourin Med 1992; 68:209-216.
34. Prakash M, Patterson S, Gotch F, et al. Ex vivo analysis of HIV-1 co-receptors at the endocervical mucosa of women using oral contraceptives. BJOG 2004; 111:1468-1470.
35. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003; 38:13-22.
36. White HD, Crassi KM, Givan AL, et al. CD3+ CD8+ CTL activity within the human female reproductive tract: Influence of stage of the menstrual cycle and menopause. J Immunol 1997; 158:3017-3027.
37. Ghanem KG, Shah N, Klein RS, et al. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis 2005; 191:358-366.
38. Ildgruben AK, Sjoberg IM, Hammarstrom ML. Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol 2003; 102:571-582.
39. Cohen MS, Britigan BE, French M, et al. Preliminary observations on lactoferrin secretion in human vaginal mucus: Variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae. Am J Obstet Gynecol 1987; 157:1122-1125.
40. Ryu J, Choi H, Min D, et al. Effect of iron on the virulence of Trichomonas vaginalis. J Parasitol 2001; 87:457-460.
41. Alderete J, Provenzano D, Lehker M. Iron mediates Trichomonas vaginalis resistance to complement lysis. Microb Pathog 1995; 19:93-103.
42. Lehker M, Arroyo R, Alderete J. The Regulation by iron of the synthesis of adhesins and cytoadherence levels in the protozoan Trichomonas vaginalis. J Exp Med 1991; 174:311-318.
43. Sugarman B, Mummaw N. Oestrogen binding by and effect of estrogen on trichomonads and bacteria. J Med Microbiol 1990; 32:227-232.
44. Ford LC, Hammill HA, DeLange RJ, et al. Determination of estrogen and androgen receptors in Trichomonas vaginalis and the effects of antihormones. Am J Obstet Gynecol 1987; 156: 1119-1121.
45. Sugarman B, Mummaw N. The effect of hormones on Trichomonas vaginalis. J Gen Microbiol 1988; 134:1623-1628.
46. Sharma R, Pickering J, Mccormack W. Trichomoniasis in a postmenopausal women cured after discontinuation of estrogen replacement therapy. Sex Transm Dis 1997; 24:543-545.
47. Ildgruben A, Sjoberg I, Hammarstrom ML, et al. Steroid receptor expression in vaginal epithelium of healthy fertile women and influences of hormonal contraceptive usage. Contraception 2005; 72:383-392.
48. Rothman K, Greenland S. Modern Epidemiology, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
49. Paavonen J. Physiology and ecology of the vagina. Scand J Infect Dis Suppl 1983; 40:31-35.